Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.20 |
---|---|
High | 9.25 |
Low | 8.80 |
Bid | 8.65 |
Offer | 8.95 |
Previous close | 9.35 |
Average volume | 9.57 |
---|---|
Shares outstanding | 43.22m |
Free float | 42.59m |
P/E (TTM) | -- |
Market cap | 453.33m USD |
EPS (TTM) | -3.54 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 18:32 BST.
More ▼
Press releases
- KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
- KalVista Appoints Brian Piekos as Chief Financial Officer
- KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024
- KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
- KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium
- KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema
- KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
- KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11
More ▼